Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
Want to see GB:AGY full AI Analyst Report?
AGY Stock Chart & Stats
11.80 p
-0.04 p(-0.55%)
At close: 4:00 PM EST
11.80 p
-0.04 p(-0.55%)
Day’s Range― - ―
52-Week Range6.50 p - 12.10 p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£538.26M
Enterprise Value470.45M
Total Cash (Recent Filing)£10.08M
Total Debt (Recent Filing)£26.75M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£68.00M
Bulls Say, Bears Say
Bulls Say
Specialized Immunotherapy FocusAllergy Therapeutics' core business targets disease‑modifying allergy immunotherapies rather than symptomatic care. That durable business model addresses root causes, supports longer treatment courses, and creates stronger physician and payer relationships versus ad hoc symptomatic products, sustaining long‑term relevance in allergy care.
R&D Pipeline For Next‑generation TreatmentsA dedicated pipeline for next‑generation allergy therapies provides structural upside: successful clinical or regulatory advances can yield differentiated products with patentable features, licensing or partnership value, and a multi‑year growth runway that supports a recovery in commercial traction if clinical progress continues.
Operating In Specialty Pharma/biologicsExposure to the specialty pharma/biologics segment gives structural advantages: higher technical barriers to entry, specialist sales channels, and payer reimbursement pathways. These factors can preserve pricing power and margins over time for differentiated allergy immunotherapies versus commodity OTC treatments.
Bears Say
Declining Revenue And Large LossesA sustained revenue decline and very large net losses materially weaken the company's ability to invest in commercialization and clinical programs. Over several months this undermines scale economics, increases reliance on external capital, and raises the risk that pipeline and market access plans cannot be fully executed.
Negative Equity And High LeverageNegative shareholders' equity and elevated leverage constrain financial flexibility and increase refinancing and covenant risks. Structurally, this limits the company's ability to fund trials, pursue partnerships, or sustain operations without dilutive equity raises or costly borrowing, impairing long‑term strategic options.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flows indicate the business is not self‑funding its operations or R&D. Over a multi‑month horizon this necessitates external financing, increasing dilution or debt service burdens, and can force prioritization or scaling back of commercial and development programs.
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 6.50 p and its highest was 12.10 p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £538.26M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 112 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -0.004 p earnings per share for the quarter, the consensus estimate of -0.004 p by 0 p.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -0.004 p in its last earnings report, expectations of -0.004 p. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.35%
12-Months-Change
Fundamentals
Return on Equity
409.00%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---